10th Annual

Fragment-Based Drug Discovery

From Hits to Leads and Lessons Learned

April 22-23, 2015 


A mutli-disciplinary gathering where you can gain new insights and refresh on new ideas
through networking and presentations

Djamal B., Arisan Therapeutics

Fragment-based approaches to find new small molecule drug candidates are now part of most drug discovery campaigns. The challenge of fragment-based drug design campaigns has always been progressing fragment hits against the target compound to obtaining a clinical candidate. Via case studies on success stories and compounds moving forward or not in preclinical development, this conference will highlight best practices and pitfalls to avoid. Join fellow drug discovery colleagues for this day-and-a-half meeting in the second half of CHI’s larger Drug Discovery Chemistry event.

Preliminary Agenda

Plenary Keynote

Fragment-Based Drug Discovery: A Fifteen Year (Re-)Evolution

Harren Jhoti, Ph.D., President & CEO, Astex Pharmaceuticals


Irreversible Tethering: Fragment-Based Drug Discovery Technology for Covalent Enzyme and PPI Inhibitor Discovery

Alexander Statsyuk, Ph.D., Assistant Professor, Chemistry Department, Northwestern University

Fragment Hopping to Design Selective Inhibitors for Beta-catenin/T Cell Factor Interactions

Haitao (Mark) Ji, Ph.D., Assistant Professor, Chemistry, University of Utah

Using Fragment-Based Lead Discovery towards Alternate Mechanisms: Inhibiting Ubiquitin Binding to USP7

Till Maurer, Ph.D., Senior Scientist, Structural Biology, Genentech

Identification of Fragment Hits that Bind the SAM Pocket of COMT

Mark Hixon, Ph.D., Principal Scientist, Medicinal Chemistry, Takeda


Attacking Cancer with Fragments: BCL2 Case Studies

Andrew Petros, Ph.D., Associate Research Fellow, Research & Development, AbbVie

Choosing and Using Fragments in Lead Discovery

Roderick E. Hubbard, Ph.D., Vernalis Research and University of York



Experiences with Fragment Libraries at Astex

Alison Woolford, Ph.D., Associate Director, Chemistry, Astex Pharmaceuticals

Ligand Deconstruction and Library Design: Why Some Fragment Positions are Conserved and Others are Not

Sandor Vajda, Ph.D., Professor, Biomedical Engineering and Chemistry, Boston University

Exploring Possible Drug Target Conformational Changes by Fragment Screening

Barry Finzel, Ph.D., Professor, Medicinal Chemistry, University of Minnesota

Fragment-to-Lead Case Study: Optimization of a Non-Kinase Target

Chris McBride, Staff Scientist, Medicinal Chemistry, Takeda

The Application of Extended Huckel Theory for Pharmacophore Modeling

Alain Ajamian, Ph.D., Director, Chemical Computing Group

Rocky Goldsmith, Ph.D., Applications Scientist, Chemical Computing Group

For more details on the conference, please contact:
Anjani Shah, Ph.D.
Conference Director
Cambridge Healthtech Institute
Phone: (914) 723-0255
Email: ashah@healthtech.com 

For partnering and sponsorship information, please contact:
Carolyn Benton
Business Development Manager
Cambridge Healthtech Institute
Phone: (+1) 781-972-5412
Email: cbenton@healthtech.com